10X Genomics Inc reports results for the quarter ended December 31 - Earnings Summary

10x Genomics

12/02/2025 22:41

* 10X Genomics Inc  TXG.OQ  reported a quarterly adjusted
loss
of 40 cents​​ per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of -41 cents.  The mean expectation of
nineteen analysts for the quarter was for a loss of 29 cents per
share. Wall Street expected results to range from -38 cents
to -14 cents per share.
    * Revenue fell 10.3% to $165.02 million from a year ago;
analysts
expected $159.39 million. 
    * 10X Genomics Inc's reported EPS for the quarter was a loss
of 40
cents​.
    * The company reported a quarterly loss of $49.03 million.
    * 10X Genomics Inc shares had fallen by 17.7% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 10
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc
is $20.00 
This summary was machine generated from LSEG data February 12 at
10:40 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.29          -0.40          Missed
 Sep. 30 2024      -0.34          -0.30          Beat
 Jun. 30 2024      -0.48          -0.32          Beat
 Mar. 31 2024      -0.50          -0.50          Met